Pegfilgrastim to prevent low white blood cells in triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This study tests whether a medicine called pegfilgrastim can help prevent dangerously low white blood cell counts in women with triple-negative breast cancer receiving a specific chemotherapy combination. Low white blood cells increase infection risk, so this medicine may help patients stay safer during treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with triple-negative breast cancer (a specific type confirmed by biopsy or cell sample)
- Your cancer is stage II or III (medium to advanced, but not spread to distant organs)
- You are between 19 and 70 years old
- You have not received any chemotherapy before this study
- Your liver, kidneys, and blood counts are healthy enough to handle chemotherapy
- You are able to give written consent and follow study instructions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized cancer vaccine for triple negative breast cancer. It is given alongside standard chemotherapy and immunotherapy to help your immune system fight the cancer.
This trial tests a medicine (tripegfilgrastim) that helps prevent a serious drop in white blood cells (severe neutropenia) caused by certain chemotherapy. It is for people with advanced pancreatic or bile duct cancer who are starting a new treatment.
This trial tests whether a drug called sacituzumab govitecan can help prevent a low white blood cell count (neutropenia) in people with metastatic triple-negative breast cancer. It is for patients who have already received some chemotherapy but need a new treatment option.
This trial tests a once-per-cycle injection (Telpegfilgrastim) to help keep your white blood cell count from dropping dangerously low during chemotherapy. It is for people with solid tumors who are at increased risk for neutropenia (low infection-fighting cells).
This trial compares two drugs (Telpegfilgrastim and Filgrastim) to help prevent dangerously low white blood cell counts after chemotherapy in children and young adults with solid tumors. It's for patients who have already had this problem in a previous chemo round.
This trial tests if a study drug (Thiopegfilgrastim) can help prevent a dangerous drop in white blood cells (bone marrow suppression) in people with esophageal or lung cancer who are getting chemo and radiation. It may reduce your risk of infection during treatment.
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.